Recombinant von Willebrand factor (rVWF) may be safe and well tolerated in patients with type 3 and severe type 1 von Willebrand disease, according to interim data from a Phase 1 multicenter, international clinical study presented today at the 52nd Annual Meeting of the American Society of Hematology. The interim data from 22 patients in the 32-patient study also suggest rVWF has a pharmacokinetic profile that is comparable to plasma-derived von Willebrand factor (pdVWF), the current standard for treatment for patients with the disease. The condition is associated with prolonged bleeding times, and the resulting complications can, in some cases, be considered life-threatening.
"Baxter is applying its scientific leadership in hemophilia to improve care for patients with other bleeding disorders," said Bruce Ewenstein, M.D., Ph.D., vice president, clinical affairs at Baxter. "Providing patients and physicians with a plasma- and albumin-free, recombinant treatment option for a condition that is as challenging to treat as von Willebrand disease is an important focus for Baxter's clinical research and development efforts."
Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial